Table 1.
Demographic and clinical data of the participants of the study.
| DLB (n = 59) | AD (n = 28) | PD (n = 24) | CTRLs (n = 51) | p 1 | |
|---|---|---|---|---|---|
| Mean age, y 2 (age range, y) | 75.1 (57–89) | 73.9 (65–82) | 66.9 (42–87) | 72.0 (61–85) | 0.0067 |
| Gender (male/female ratio) | 1.5:1 | 1:1.5 | 1.5:1 | 1:1.5 | 0.493 |
| Disease duration 3, y (range, y) | 4.2 (1.2–10.1) | 3.4 (0.8–5.6) | 5.2 (1.8–7.6) | - | 0.068 |
| MMSE 4, mean (range) | 15.1 (3–28) | 20.3 (6–28) | - | - | 0.189 |
| UPDRS-III 5, mean (range) | - | - | 20.9 (5–39) | - | - |
| GDS 6, mean (range) | - | 4.1 (3–6) | - | - | - |
| Parkinsonism, n (%) | 47 (79.7%) | - | - | - | - |
| Positive DAT imaging, n (%) | 55 (93.2%) | - | - | - | - |
1 p, obtained by the Kruskal-Wallis test; 2 y, years; 3 from the beginning of cognitive symptoms for DLB and AD, and motor symptoms in the case of PD; 4 MMSE, Mini-Mental State Examination; 5 UPDRs-III, Unified Parkinson’s disease rating scale; 6 GDS, global deterioration scale.